A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting
Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Peter Valent(Medical University of Vienna), Thamer Sliwa(Hanusch Hospital), Alois Lang(Landeskrankenhaus Feldkirch), Clemens Dormann(Ordensklinikum Linz Barmherzige Schwestern), Richard Greil(Paracelsus Medical University), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Shanow Uthman(Novartis (Austria)), Niklas Muenchmeier(Novartis (Austria)), Albert Wölfler(Medical University of Graz), Wolfgang R. Sperr(Medical University of Vienna), Stefan Schmidt(Innsbruck Medical University), Petra Pichler(Universitätsklinikum St. Pölten), Sonja Burgstaller(Klinikum Wels-Grieskirchen), F. Göebel(Novartis (Austria)), Christoph Tinchon(LKH Hochsteiermark)
Cited by 0
Related Papers
Diagnostic criteria and classification of mastocytosis: a consensus proposal
|Leukemia Research|2001|1.1k
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.
|The Journal of Experimental Medicine|1984|1.1k
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540